DERMATA THERAPEUTICS INC

DRMANASDAQ

🏆 #3898 by market capUS Equity

$1.08▼ $0.04 (−3.57%)

🌙 After hours$1.61▲ 49.06%Regular close · extended-hours price shown

1h—

24h▼ 3.6%

7d▼ 7.7%

14d▼ 8.1%

30d▼ 19.7%

1y▼ 82.3%

🏦Market Cap

$4M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

Trading Snapshot

Day Range: $1.08 – $1.10
52-Week Range: $0.95 – $6.67
Volume: $4.98B
Avg Volume: $3.89B
Shares Outstanding: 4.0M
Next Earnings: Oct 17, 2026

Fundamentals Snapshot

Annual Revenue: $371,077
Last Q Revenue: $101,702
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-5.43
Dividend Yield: —

Why Investors Own DRMA

✓High-growth profile — revenue up +58.3% YoY with expanding US Equity exposure.
✓Healthy economics — 31% gross margin and 10% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$371,077▲ +65.3% YoY

Gross Margin (TTM)

30.9%▲ +1.5% YoY

Operating Income (TTM)

$99,820▲ +65.3% YoY

Free Cash Flow (TTM)

$35,994▲ +65.3% YoY

About DERMATA THERAPEUTICS INC

Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.

🦦